NCT04869943: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+, AR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Endocrine (Hormone Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have received at least 2 prior lines of treatment in MBC setting which must have included both an AI (monotherapy or combination & fulvestrant (monotherapy or combination); at least one must have been given in combination with a CDK 4/6 inhibitor
Exclusions: Patients with active untreated brain metastasis requiring local therapy – see trial for details; Patients who did not previously respond (had disease progression) within 6 months to one of the following treatments: 1) fulvestrant monotherapy, 2) fulvestrant plus CDK 4/6 inhibitor, 3) nonsteroidal aromatase inhibitor monotherapy, or 4) nonsteroidal aromatase inhibitor plus CDK 4/6 inhibitor for MBC

Comments are closed.

Up ↑